Due to unforeseen scheduling conflicts, the RASCALS Foundation regrets to announce that its 3rd Annual 5K Walk/Run has been postponed to a later date.
“Jon Imber’s Left Hand” picks up at the start of what Imber calls “my ALS summer.” It is a story about the artist and his wife, the painter Jill Hoy. The pair for decades have been key members of the Stonington and Maine painting communities. While Imber is the object of the film, Hoy is its true subject.
Why are military veterans, particularly those who served in the First Gulf War, twice as likely to get ALS when compared to the rest of the population? Since 2008, the Veterans Administration has recognized that there’s a clear link between ALS and military service, and the agency considers it to be a service-connected disability.
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS).
According to Brian Kaspar, MD, a principal investigator in the Center for Gene Therapy at Nationwide Children’s and senior author of the new study, inhibiting NF-kB in microglia decreased ALS progression by 47 percent. “
While the size of this study is small, the ability of the specific biomarkers used to predict ALS prognosis suggests that the approach holds promise.
Research led by King’s College London has identified a new genetic variant, located on chromosome 17, associated with sporadic amyotrophic lateral sclerosis (ALS) – the most common form of motor neurone disease (MND).
“We are very excited to announce the selection of IMS-088 as ImStar’s lead ALS compound. As we continue with preclinical development next year, we hope to establish IMS-088 as a safe and effective new drug candidate for ALS,” said Jean-Pierre Julien, ImStar’s chief scientific officer.
According to a post hoc analysis, a greater percentage of patients receiving NP001 experienced a halt in disease progression which reached statistical significance when compared to the combination of concurrent and matched historical (placebo) controls. The high dose of NP001 (2mg/kg) halted progression in 27% of patients compared to 11% of patients on placebo. Further, NP001 was found to be safe and well-tolerated in the study.
Cytokinetics will elaborate on the clinical trial design and include enrollment and baseline demographics data from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS), which is evaluating tirasemtiv, a novel mechanism skeletal muscle activator, as a potential treatment for patients with amyotrophic lateral sclerosis (ALS).